Browse Articles
Discover research articles across all indexed journals
Paraneoplastic and symptomatic score for prediction of overall and cancer-specific survival in patients with renal cell carcinoma.
527 Background: Patients presenting with symptomatic renal cell carcinoma (RCC) tend to have more aggressive disease and poorer prognosis. Paraneoplastic syndromes (PNS), manifesting as atypical symptoms or abnormal laboratory values, are similarly associated with worse outcomes. However, the impact of symptoms and PNS on prognosis remains unclear. The aim of this study is to develop a Paraneoplastic and Symptomatic Score (PNSS) to better predict prognosis by considering clinical presentation and the presence of PNS at diagnosis. Methods: Prospectively collected data from 5743 T1-T4, N0/1, M0/1 RCC patients treated with surgery across four centers (UC San Diego, IRCCS San Raffaele, Emory University, Tokyo Medical and Dental University) were retrospectively analyzed. The PNSS was developed using preoperative variables: hematuria, flank pain, fever, nausea/vomiting/appetite loss, anemia (<11.5 g/dL for women and <12.5 g/dL for men), hypoalbuminemia (<3.5 g/dL), hypercalcemia (>10.5 mg/dL), elevated De Ritis ratio (AST/ALT>1.25), elevated C-reactive protein (>5 mg/dL), polycythemia (hematocrit >47% for women, >53% for men) and leukocytosis (WBC>11x10^9/L). Patients were stratified into four categories: Low PNSS=0; Favorable-intermediate=1-2; Unfavorable-intermediate=1-2 + Anemia; High PNSS ≥3. Multivariable Cox regression analyses (MVA) tested the association of PNSS categories with overall (OS) and cancer-specific survival (CSS). Kaplan-Meier analysis (KMA) was used to show survival differences among groups. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to assess the score's predictive validity for OS and CSS. Results: Of the 5743 patients, 48% (n=2770) were classified as Low PNSS, 29% (n=1656) as Favorable-intermediate, 17% (n=982) as Unfavorable-intermediate and 6% (n=335) as High PNSS. At MVA, increasing PNSS was significantly associated with worse OS and CSS (all p<0.05). High PNSS patients had the highest hazard ratios (HR) for OS [HR=6.5; 95% Confidence Interval (95CI)=4.4-9.5; p<0.05) and CSS (HR=9.6; 95CI=5.4-16.8; p<0.05). KMA showed a clear separation of survival curves across PNSS categories (log-rank p<0.001). Five-year OS rates were 92% (95CI=91-94) for Low, 84% (82-86) for Favorable-intermediate, 68% (65-72) for Unfavorable-intermediate and 47% (42-54) for High, while 5-year CSS rates were 96% (95-97), 91% (89-93), 79% (76-82) and 60% (53-67), respectively. ROC AUCs were 0.70 for OS and 0.71 for CSS, indicating strong predictive accuracy. Conclusions: Increasing PNSS scores were significantly associated with worse oncological outcomes. The PNSS represents a comprehensive tool for predicting overall and cancer-specific survival in RCC patients. Including PNSS in preoperative assessments aids in identifying patients at higher risk and guiding clinical decision-making.
Natural color composition induces oddball P3 asymmetry associated with processing fluency
Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.
618 Background: Radiation or chemotherapy represent the standard treatment in clinical stage IIA/B seminoma. Despite high cure rates both modalities are associated with significant long-term toxicities. The COTRIMS trial evaluated the oncological and functional efficacy of primary retroperitoneal lymphadenectomy (RPLND) without adjuvant chemotherapy in CS IIA/B seminomas. Methods: 34 patients with CS IIA/B pure semimomas were prospectively recruited. Exclusion criteria were adjuvant chemotherapy following orchiectomy, CS IIC, previous retroperitoneal surgery or radiation, positive tumor markers. All patients underwent nerve sparing RPLND with a unilateral template; no adjuvant chemotherapy was delivered. Follow-up was done according to EAU guidelines. In 22 patients miR371 was evaluated preoperatively and correlated with pathohistology of lymph nodes. The primary endpoint of the study was a relapse-free rate of < 20% at 3 years. Results: Median age is 34.2 (21-54) years, mean and median follow-up is 41.5 (4-73) and 33.4 (13-56) months. 22 and 12 pts had CS IIA and CS IIB, resp. Mean OR-time, blood loss and hospitalisation were 131 (105-195) min, < 150ml and 4 (3-9) days. 4 (11.7%) pts experienced Clavien Dindo 3a complication. Antegrade ejaculation was preserved in 88%. A mean of 19 (7-57) lymph nodes were dissected. Mean number of positive lymph nodes was 1.4 (1-2), mean diameter was 2.3 (0.8-4.1) cm. Seminoma was present in 85%, non-malignancy and nonseminoma were found in 8.9% and 5.9%. miR371 was positive in 17/18 pts with metastases und negative in 3/3 with benign lesions. 4 (11.7%) pts relapsed after 4, 6, 9 and 12 months and all were salvaged by chemotherapy. Conclusions: RPLND results in high cure rates associated with low frequency of surgery – related complication even after a follow-up of about 3 years. Nearly 90% of patients can be managed without systemic chemotherapy. RPLNSD should be included in the treatment options for CS IIA/B seminomas. miR371 appears to be a valid biomarker to predict presence of lymph node metastases. Clinical trial information: DRKS00025384 .
Safety evaluation of stereotactic body radiation therapy (SBRT) during lutetium-177-PSMA-617 (177Lu-PSMA-617) treatment for patients with metastatic prostate cancer.
129 Background: Few studies have explored the use of focal therapies to address select sites of resistant disease in men receiving 177-Lu-PSMA-617 for metastatic castrate resistant prostate cancer (mCRPC). Our institutional practice is to offer SBRT for patients with up to 5 sites of oligoprogression or non-responding lesions while undergoing 177Lu-PSMA-617 (every 6 weeks for 6 cycles total). This is determined by PSMA or choline PET imaging during the course of 177Lu-PSMA-617. Herein, we evaluated the safety of adding target SBRT during treatment with 177Lu-PSMA-617. Methods: This retrospective single institution analysis was conducted via systematic chart review to evaluate for adverse events during or after treatment. Grading of treatment-related adverse events was conducted using Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5). Results: Thirty-one patients receiving 177Lu-PSMA-617 with 51 sites of oligoprogressive or non-responding metastatic disease were treated with SBRT. The median number of sites treated was 1 (range 1-4). Most patients received SBRT immediately after cycle 6 (32%) or after cycle 3 or 4 (42%). Bone was the most commonly treated site of disease (90%) with the majority (54%) of bone sites being spine or sacrum, followed by lymph nodes (10%). Ultimately, 84% of patients completed all 6 cycles of 177Lu-PSMA-617 (range 4-6). The median follow-up time was 19.1 months (IQR 15.5-22.4) after 177Lu-PSMA-617 therapy start. A total of 2 patients experienced a pathologic fracture within the SBRT treatment field that could possibly be related to radiotherapy. One patient experienced a grade 2 neuropathy which may have been related to radiation therapy. Other potential adverse events are listed (Table). Conclusions: Our data demonstrates a low rate of significant toxicity with the use SBRT during treatment with 177Lu-PSMA-617. Further study is indicated to determine the oncologic efficacy and potential late side effects of this treatment strategy. Adverse events. Event All Grades Grade > 3 Any Adverse Event 104 2 Anemia 29 (94%) 0 Low Platelets 11 (35.5%) 1 (3.2%) Any Pathologic Fracture 7 (22.5%) 1 (3.2%) Possible SBRT-related Pathologic Fracture 2 (6.5%) 1 (3.2%) Bone Pain Flare 3 (9.6%) 0 Neuropathy 1 (3.2%) 0
A single-institution experience of pneumonitis in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
475 Background: Immunotherapy (IO) has dramatically changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). The expanded use of IO in mRCC has led to an increased risk of immune-related adverse events (irAEs) in this population. Pneumonitis is an uncommon but potentially fatal irAE. Data describing the incidence of pneumonitis among mRCC patients treated with IO are sparse and the clinical experience of these patients is not widely described. Methods: We retrospectively identified patients with mRCC who received IO therapy at the University of Virginia and investigated the incidence of pneumonitis in this population. Clinical, radiologic, and pathologic features of pneumonitis were collected and analyzed by a multidisciplinary team of medical oncologists, pulmonologists, and radiologists. Images were reviewed by two independent radiologists. Associations among pneumonitis incidence, therapy received, and patient characteristics were examined using univariate regression models with p-values adjusted using the Benjamini-Hochberg algorithm, as well as associations between clinical and radiologic features of pneumonitis and outcomes. Results: Data were available for 146 patients with mRCC who received IO as first- (n=117) or second- (n=29) line treatment. The overall incidence of pneumonitis in our cohort was 8.9%. Pneumonitis occurred in 9.4% of patients who received IO as first line therapy and 6.9% of second line. Incidence was 10.8% among those treated with IO/IO, 10% with IO/TKI, and 4.7% with IO monotherapy. Fifty-four percent of patients who developed pneumonitis had received prior chest radiation vs 11% who did not develop pneumonitis (p-adj: 0.014). Eight of the 13 pneumonitis cases (61.5%) were grade 1 to 2, and 85% improved/resolved with drug holding and/or steroid administration. Five patients were rechallenged with IO and two experienced recurrent pneumonitis; both cases were grade 2 and resolved with oral steroids. Two patients worsened clinically after initial pneumonitis diagnosis and died during management; cause of death was attributable to pneumonitis in one patient and multifactorial in the other. Radiologic and pathologic features of pneumonitis were diverse and not significantly associated with severity or clinical outcome. Conclusions: Our study describes the variable clinical, radiologic, and pathologic characteristics of IO-associated pneumonitis in a single institution mRCC population. Our analysis suggests that incidence of pneumonitis in our mRCC population may be associated with prior receipt of chest radiation. Most cases of pneumonitis in our study were mild and successfully managed, however two patients had worsening symptoms despite escalating treatment and did not survive. Broader investigation of the incidence, causes, and clinical experience of pneumonitis in mRCC is needed.
Publisher Correction: Nasal carriage of MRSA among clinically affiliated undergraduate students at the College of Health and Medical Sciences, Haramaya University, Ethiopia
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.
TPS435 Background: Biochemical recurrence (BCR) develops in 20%–50% of patients with prostate cancer (PCa) after initial definitive treatment and is associated with an increased risk of distant metastasis and mortality (1). Despite significant advances, the most effective treatments for BCR often involve long-term toxicities, and most patients progress to metastatic disease (2). Thus, there is an unmet need for therapies with durable and deep responses without the long-term side effects and impaired health related quality of life associated with prolonged androgen deprivation therapy (ADT). In different tumor entities bispecific T-cell engagers (BITEs) may have better efficacy and safety in earlier stages of the disease (3). Xaluritamig, a BITE, simultaneously engages the six-transmembrane epithelial antigen of the prostate 1 (STEAP1) expressed on PCa cells and the CD3 complex on T cells, leading to T-cell mediated lysis of the STEAP1 expressing PCa cells. In an ongoing trial (NCT04221542), xaluritamig has demonstrated encouraging responses in patients with metastatic castration-resistant PCa. In the current study, safety, tolerability, and preliminary efficacy of xaluritamig are evaluated in patients with high-risk BCR. Methods: This Phase 1b, open-label, multicenter study aims to enroll approximately 40 patients diagnosed with high-risk BCR following definitive therapy. Eligibility criteria include histologically or cytologically confirmed prostate adenocarcinoma with BCR (defined as screening prostate specific antigen [PSA] ≥1 ng/mL after radical prostatectomy [RP], or ≥2 ng/mL after radiotherapy [XRT]); initial treatment with definitive therapy (either RP or XRT, or both); PSA doubling time of ≤12 months; and no evidence of metastasis in conventional imaging (PSMA-PET only positive imaging is allowed). The study includes a 28-day screening period, a six-cycle treatment period (each cycle lasting 28 days), a safety follow-up visit (30 days post-treatment), and a long-term follow-up period (up to 36 months). Xaluritamig will be administered as a short-term intravenous infusion over six cycles as monotherapy without ADT. Primary outcomes evaluate safety and tolerability through treatment-emergent and treatment-related adverse events. Secondary outcomes assess PSA response rates, time to progression, time to additional therapies, metastasis-free survival, treatment completion, and pharmacokinetics of xaluritamig. Statistical analysis for safety will include all enrolled patients receiving at least one dose of xaluritamig. Enrollment began in September 2024 and is ongoing. 1. Shore ND et al. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):192-201. 2. Nguyen PL et al. Eur Urol. 2015;67(5):825-836. 3. Litzow MR et al. N Engl J Med. 2024;391(4):320-333. Clinical trial information: NCT06555796 .
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
Absence of prostate cancer events after 3 years of tailored screening in high-risk individuals with germline pathogenic variants in DNA repair genes.
337 Background: The increasing focus on patient-centered care and the development of precision medicine emphasize the need for alternative screening pathways for high-risk individuals. Family history is a significant risk factor for prostate cancer (PCa), and identifying patients with a genetic predisposition is crucial. The discovery of germline pathogenic variants (PVs) in DNA repair genes (DRGs) underscores the importance of a dedicated screening approach. This study aimed to evaluate the effectiveness and compliance of a tailored screening protocol in that population, incorporating the Prostate Health Index (PHI) and multiparametric MRI (mpMRI). Methods: This prospective study, based on a novel concept of a dedicated screening protocol and funded by AIRC (project IG 2020 ID 25027), was conducted at a tertiary hospital in collaboration with department of Oncology, Urology, Pathology, Radiology, and Medical Genetics. The study included men aged 35-69 with documented PVs in DRGs who consented to participate in the screening protocol. Probands were recruited in two categories: Male relatives of women with PVs in DRGs who were affected by breast or ovarian cancer; Male relatives of men with PVs in DRGs diagnosed with high-grade PCa (ISUP >2). Participants underwent annual PSA testing, PHI assessments, digital rectal examinations (DRE), and mpMRI based on individual risk stratification (PHI<20, 20<PHI<40, PHI>40). Results: Between 2021 and 2024, 102 patients were enrolled, with a median age of 52 years (IQR 46-61). Of these, 100 were from the women’s cohort, and 2 were from the men’s cohort. The median PSA level was 0.9 ng/mL (IQR 0.5-1.7), and the median PHI was 17 (IQR 12.0-23.2). The distribution of pathogenic variants (PVs) included BRCA2 (56.1%), BRCA1 (18.6%), ATM (4.92%), PMS2 (2.94%), and other less frequent PVs. Screening compliance was high, with 95% of patients completing the T1 visit, 86% completing the T2 visit, and 100% completing the T3 visit. Among patients with PHI >20 and <40, 81.5% underwent mpMRI. Only one patient had a positive mpMRI result and underwent a biopsy, which was negative for PCa. An additional three patients underwent biopsy due to clinical suspicion, with all resulting negative. Of those with PHI >40, 66.7% underwent mpMRI and, as per protocol, a biopsy, which also resulted negative for PCa. Interestingly, at T2, 33.3% of patients with PSA >3 had a PHI <20, thereby avoiding the need for mpMRI. Despite no cases of PCa being detected after three years of follow-up, two patients were diagnosed with bladder cancer (BC). Conclusions: This study demonstrated, so far, a low effectiveness in diagnosing prostate cancer (PCa), with no cases identified, in contrast to the results of the referral IMPACT study. However, compliance with the screening protocol was high, and the two cases of bladder cancer (BC) raise new perspectives on the role of PVs in DRGs and their relationship with urological neoplasms. Enrollment in the study is ongoing, and further follow-up may provide additional insights.
Multi-scale differences in landscape connectivity evaluation and protection strategies: a case study of Chongqing, China
Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine ( <sup>18</sup> F) or PSMA ( <sup>68</sup> Ga) PET/CT for target dose-escalation.
326 Background: Fluciclovine PET-guided prostate cancer (PCa) radiotherapy (XRT) improves failure-free survival (FFS) over conventional imaging (CI) alone in post-prostatectomy (RRP) recurrence (EMPIRE-1, PMID: 33971152). In this randomized trial we explored dose-escalation (DE) to sites of PET uptake (not done in EMPIRE-1) using either fluciclovine or 68 GaPSMA PET/CT-guided XRT and compared cancer control to the fluciclovine PET arm of EMPIRE-1 2Y failure free survival (FFS) of 79.6%. Methods: From 2019-2023, 140 pts w/ PCa with detectable PSA post-RRP & negative CI were stratified by: (a) PSA (<1.0 v ≥ 1.0 ng/mL), (b) adverse path [+ECE, +SV, +margin, +node] (0 v any) & (c) ADT (Y v N) & randomized to XRT directed by fluciclovine (Arm 1) v 68 GaPSMA (Arm 2). In both Arms, XRT decisions were PET determined: (A) extrapelvic (EP) uptake (no XRT); (B) pelvic uptake (XRT to pelvis + prostate bed [PB]); (C) PB only uptake (XRT to PB); & (D) no uptake (XRT to PB). Pelvic dose: 45.0-50.4/1.8 Gy (with optional DE {to PET uptake} up to 56 Gy); PB dose: 64.8-70.2 Gy (with optional DE up to 76 Gy). Failure was defined as in EMPIRE-1. Primary endpoint, declared a priori, was 2Y FFS comparing entire cohort [Arms (1+2)] to the 79.6% 2Y FFS of the fluciclovine PET arm of EMPIRE-1 using Z-test. KM curves for Arms 1 & 2 were compared using log-rank test. Univariate (UV) & multivariable (MV) analyses were performed by Cox proportional hazards model on demographic, disease, & treatment factors. Provider-reported [acute & late, GI & GU] toxicities were compared using χ 2 test. Results: 140 pts were enrolled (Arm 1: 70; Arm 2: 70). Arms were balanced on age, race, PSA, GG, ECE, SV, margin, node, & ADT use. 5 pts in Arm 1 and 1 pt in Arm 2 withdrew before PET. For pts completing XRT (Arm 1: 59; Arm 2: 60), median FU was 2.00 years. For primary endpoint, 2Y FFS for Arm (1+2) 87.4 v 79.6% target from EMPIRE-1 (p=0.018). There were no significant differences in 2Y FFS between Arm 1 v Arm 2 (88.2% v 86.9%, p=0.604). PET uptake in Arms 1 v 2 were: EP: 5 v 8; pelvic+/-PB: 10 v 10; PB only: 47 v 24; none: 3 v 27. Typical PB DE (n=74) was 74 Gy & pelvis DE (n= 16) was 55 Gy. For Arm 1 v Arm 2, covariates reaching p <0.10 on UV analysis were: +SV (p=0.010), +margin (p=0.039), PB uptake (p=0.068), & PB boost (p=0.085), and on MV analyses were: +SV (p=0.004), ADT (p=0.067), +margin (p=0.069), & PB boost (p=0.096). Toxicity was similar & low in both Arms 1 & 2. Conclusions: Although fluciclovine had higher diagnostic yield in the PB & 68 GaPSMA had higher yield for EP disease, both radiotracers had similar yield in the pelvic LN, & both radiotracers had similar impact on FFS in this setting. Integrating either fluciclovine or 68 GaPSMA into post-RRP XRT planning for DE to sites of PET uptake in PB or pelvis resulted in improved FFS over a prior trial in which no DE was performed; other factors may also have contributed to this observed difference. Clinical trial information: NCT03762759 .
Targeting highly aggressive ductal prostate tumours with poly ADP ribose polymerase inhibitor (PARPi) and androgen receptor signaling inhibitor (ARSi) combination therapy.
420 Background: Prostatic ductal adenocarcinoma (DAC) is an aggressive prostate cancer variant, prone to early metastasis at low PSA levels and showing poor response to androgen blockade despite androgen receptor expression. Although DACs do not have any efficacious therapies, DACs frequently harbour DNA damage repair (DDR) mutations. We investigate the efficacy of combined PARP inhibitor (PARPi) and androgen signalling inhibitor (ARSi) therapy in DDR-proficient DAC tumours. Methods: To model DAC, organoids were developed in Matrigel from patient-derived xenografts (PDXs) originating from DDR-proficient radical prostatectomy (287R, 275R) and BRCA2 heterozygous mutant metastatic (201.1) tumours, retaining key histologic and genomic features. These organoids were exposed to different PARP inhibitors (Talazoparib, Saruparib) and androgen signalling inhibitors (Enzalutamide, Apalutamide, Darolutamide) for up to 11 days. Cell viability and growth responses were assessed using PrestoBlue and CellTiter-Glo assays and automated imaging analysis. SynergyFinder software calculated synergy scores for each treatment combination. Results were further validated in vivo using DDR-proficient 287R PDXs. Mechanistic insights were explored through RNA sequencing of 20 DAC and ten acinar radical prostatectomy samples, and four matched DAC and acinar PDXs, with γH2AX immunohistochemistry to examine DNA damage response. Results: Overall, PARPi/ARSi combination treatment significantly reduced organoid viability compared to PARPi alone or ARSi in DDR-proficient and heterozygous BRCA2 -mutant DAC tumours. The levels of synergy were comparable regardless of which PARPi and ARSi agents were combined. In vivo results using DDR-proficient PDX 287R confirmed the efficacy of PARPi + ARSi combination by reducing tumour volume by 58% compared to control ( p =0.0198) and by 40% versus PARPi alone ( p = 0.0326). Mechanistically, RNA sequencing demonstrated upregulation of multiple DDR pathways in DACs compared to acinar prostate tumours, regardless of the DDR status. After treatment with PARPi + ARSI combination, there was an increase in γH2AX compared to the control in the DDR-proficient PDX 287R (mean 1.42 vs 0.5, p=0.0056), suggesting enhanced DNA damage may contribute to the efficacy of the combination treatment. Conclusions: Our results show that PARPi increases the efficacy of ARSi in DAC. This is notable given the poor response of DAC to AR-directed treatments and provides the rationale for a pre-planned phase 1/2 study.
<i>HSD3B1</i> and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.
234 Background: The HSD3B1 gene encodes for the 3βHSD1 enzyme which regulates the rate-limiting step in potent androgen synthesis from non-gonadal precursors. The missense-encoding adrenal-permissive form of HSD3B1 generates a hyperactive 3βHSD1 enzyme compared to the adrenal-restrictive form. We aimed to test associations with OS for HSD3B1 genotyped patients randomized 1:1 to ADT vs. ADT+ENZ+AAP in the STAMPEDE platform protocol. Methods: HSD3B1 genotype was performed in germline DNA using a validated melting assay. We included patients who donated saliva or white blood cells for translational studies and were not planned for “triplet therapy with” docetaxel. Association between HSD3B1 gene and overall survival was estimated using Cox survival models adjusted for randomised group, age at randomization, WHO performance status, regular aspirin or NSAID use, planned radiotherapy and metastatic disease status. Predictive effect was estimated with the addition of an interaction term. We pre-specified M1 low volume as of primary interest given prior associations in the CHAARTED trial. Results: Germline HSD3B1 genotype was obtained for 259 men in the ADT arm and 335 men in the ADT+ENZ+AAP arm (594 total). 319 (54%) men were adrenal-permissive and 275 were adrenal-restrictive. Adrenal-permissive HSD3B1 was associated with shorter OS (HR, 1.32 [1.04-1.67, p=0.025]), which by pre-specified sub-group analysis was most strongly prognostic in low volume (N=185, HR 1.70 [1.12-2.59], p=0.012) versus M0 (N=248, HR 1.21 [0.74-1.96], p=0.442) or M1 high volume (N=161, HR 1.14 [0.78-1.67] p=0.490) Although, there was no evidence of an interaction between treatment arm and genotype (p=0.800, 0.231 and 0.480 for M0, M1 LV and M1 HV, respectively), the treatment effect in the M1 LV restrictive group was 0.37 [0.19, 0.71] versus 0.7 [0.41, 1.21] in the permissive group. Conclusions: Adrenal-permissive HSD3B1 inheritance is associated with increased risk of death in men starting long-term ADT ± ENZ+AAP in STAMPEDE. This result is consistent with prior analyses of the CHAARTED trial and prostatectomy cohorts. This effect is most notable in M1 LV and not overcome by addition of ENZ+AAP to ADT.
Asymmetric multi-band reflective metasurface for linear and circular polarizations conversion in Ku, K, Ka, and U bands
Abstract This work proposes a novel multi-band reflective metasurface, that is capable of linear polarization (LP), and circular polarization (CP) conversion in Ku, K, Ka, and U Bands. The metasurface design involves a combination of ring and square elements strategically arranged, and printed on a 0.76 mm thin-grounded Rogers RO3003 substrate. The metasurface achieves LP for y-polarized incident electromagnetic (EM) wave in 16.2–17.2 GHz, 23.0–25.4 GHz, 40.3–54.35 GHz frequency bands. The polarization conversion ratio (PCR) for LP frequency ranges is minimum 90% with an fractional bandwidth (FB) of 2.94%, 9.91%, and 26.9%, respectively. Moreover, metasurface achieves CP for y-polarized incident EM wave in 16.1–16.55 GHz, 17.5–22.15 GHz, 26.65–37.75 GHz, and 55.6–59.8 GHz frequency bands. In addition, the axial ratio (AR) for CP frequency ranges is less than 3 dB with a FB of 2.75%, 23.45%, 34.47%, and 7.27%. The device performance is considerably stable under oblique incidences up to 45 degrees. The metasurface unitcell is compact with a structural size of $$\text {length}=0.23\lambda _\circ$$ , $$\text {width}=0.23\lambda _\circ$$ and $$\text {thickness}=0.08\lambda _\circ$$ . The proposed prototype is fabricated, and the measured results are in good agreement with the simulated one. Overall, the proposed metasurface exhibits promising performance characteristics and holds potential for multiple applications in satellite based networks.
Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.
128 Background: T-cell engaging bsAbs and CAR T-cell therapy have shown exceptional success in treating multiple hematologic malignancies. More recently, bsAbs have been FDA-approved to treat uveal melanoma and small cell lung cancer, demonstrating proof-of-concept for immune therapies beyond checkpoint inhibition to effectively treat solid tumors. bsAbs and CAR-T therapies are presently undergoing evaluation in trials for patients with mCRPC. Despite early successes with these classes of therapy, there are multiple ongoing challenges including dose-limiting toxicity, ‘on-target, off-tumor’ toxicity, and immune-effector cell related toxicity. This systematic review analyzes publicly available safety derived from ongoing clinical trials. Methods: An electronic systematic search through PubMed, CINHAL, Scopus, and Ovid was done to identify phase I/II clinical trials evaluating bsAbs or CAR-T therapy in patients with mCRPC reported prior to 9/30/2024. Treatment-related adverse events (TRAE) were collected, focusing on prevalence in bsAbs versus CAR-T. A random effects model was used for analysis. Results: Eleven trials with 511 patients evaluated bsAbs, and 5 trials with 55 patents studied CAR-T therapies. Mean patient age was 67 years [95% CI: 63, 71]. Cytokine release syndrome (CRS) occurred in 49% [24, 75] of patients; 53% [17, 86] on bsAbs compared to 43% [28, 59] on CAR-T. Only 4% [2, 7] of patients had CRS grade ≥3; 14% [2, 43] on CAR-T compared to 3% [2, 6] on bsAbs (p=0.05). Neurologic TRAEs occurred in 11% [3, 31] of patients; 39% [22, 60] on CAR-T compared to 5% [2, 13] on bsAbs (p= <0.01). Hematologic TRAEs occurred in 38% [14, 71] of patients; 34% [8, 75] on CAR-T compared to 43% [9, 86] on bsAbs. Hepatic TRAEs occurred in 31% [12, 59] of patients; 25% [12, 44] on CAR-T compared to 39% [9, 81] on bsAbs (p= 0.55). However, 8% of patients [3, 20] had grade ≥3 hepatic TRAEs, with 21% [5, 51] on CAR-T versus 5% [2, 10] on bsAbs (p=0.03). Musculoskeletal/dermatologic TRAEs were seen in 30% of patients [24, 37]; 30% [24, 38] on bsAbs and 29% [8, 58] on CAR-T (p=0.89). Renal TRAEs occurred in 15% [10, 23] of patients; 21% [5, 51] on CAR-T compared to 14% [8, 24] on bsAbs (p= 0.50). Gastrointestinal TRAEs were reported in 18% [10, 33] of patients; 14% [2, 42] on CAR-T compared to 19% [9, 36] on bsAbs (p= 0.69). Conclusions: In patients with mCRPC, bsAbs and CAR-T therapies produce similar hematological, musculoskeletal/dermatologic, renal and gastrointestinal TRAE rates. However, significantly higher rates of all-grade neurologic, grade ≥3 CRS and grade ≥3 hepatic TRAEs are reported with CAR-T therapy. These data highlight the need to appreciate the differences in toxicity profiles for these two classes of therapy and to practice appropriate vigilance during treatment.
Organ perforation and fistula formation as adverse events in patients receiving tyrosine kinase inhibitors: A post-market analysis.
528 Background: Vascular Endothelial Growth Factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs), such as lenvatinib and cabozantinib, offer significant survival benefits in solid tumors, including renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma, and endometrial cancer. However, rare but serious adverse events (AEs), such as organ perforation and fistula formation, have been reported. This study evaluates the incidence and risk of these events in patients treated with VEGF-TKIs using post-marketing data from the FDA Adverse Event Reporting System (FAERS). Methods: We queried the FAERS database for reports of organ perforation and fistula formation associated with cabozantinib, lenvatinib, axitinib, and tivozanib from January 1, 2012, to June 30, 2024. A disproportionality analysis was performed using reporting odds ratios (ROR) to assess the association between VEGF-TKIs and these adverse events. Cases were categorized by organ site, with a focus on gastrointestinal (GI) tract-related events. Results: We identified 65,194 reports, including 917 cases of organ perforation and 482 cases of fistula formation. Among the perforation cases, 245 (27%) were intestinal, followed by gastric (5%). Fistula cases included 11% anal, 9% female genital tract and 6% were GI-related. Regarding TKI distribution, 19% of perforation cases were linked to cabozantinib, 35% to lenvatinib, and 46% to other TKIs (axitinib, tivozanib, or multiple TKIs). For fistula cases, 18% were associated with cabozantinib, 41% with lenvatinib, and 41% with other TKIs. Among these reports, 27% of perforations and 20% of fistulas occurred in patients with RCC. Disproportionality analysis revealed a significantly higher risk of both organ perforation (ROR: 3.41, 95% CI: 2.36–4.93) and fistula formation (ROR: 17.06, 95% CI: 14.46–20.12) in VEGF-TKI treated patients. Conclusions: Patients treated with VEGF-targeted TKIs, particularly lenvatinib, have a significantly increased risk of organ perforation and fistula formation. Lenvatinib was associated with a higher incidence of these adverse events compared to cabozantinib. These findings highlight the need for increased clinical awareness and monitoring, particularly in patients with RCC. Further research is necessary to better understand the mechanisms underlying these complications and to develop preventive strategies.
Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.
TPS884 Background: Neoadjuvant cisplatin-based chemotherapy (NACT) has demonstrated a 5-8% improvement in 5-year overall survival (OS) in patients (pts) with muscle invasive bladder cancer (MIBC). However, its routine implementation is still low due to concerns about toxicity/efficacy. Also, about 50% of pts are considered cisplatin ineligible and therefore unable to receive NACT. Immune-checkpoint inhibitors (ICI) and antibody drug conjugates (ADC) have demonstrated separately clinical activity in the perioperative setting and recently remarkable efficacy of ADC-ICIs combos has been shown in pts with advanced urothelial cancer. Therefore, combining ICIs with ADCs as a neoadjuvant therapy results an interesting approach. PRISMA-1 study will evaluate safety and efficacy of the Trop-2 directed ADC, sacituzumab govitecan (SG) in combination with the anti-PD1 zimberelimab (Z) and the anti-TIGIT domvanalimab (D) in MIBC. This study will also search for predictive biomarkers of response and will evaluate the role of ctDNA in the perioperative setting to better select for patients who need post operative treatment. Methods: PRISMA-1 study (NCT06133517) is a phase II, single arm, multicenter clinical trial that will enroll 70 adult pts with MIBC, [cT2-T4cN0-1cM0], ECOG PS 0-2, non-eligible or who refuse to receive NACT. The primary endpoint is pathological complete response (pCR) rate. Downstaging, relapse free survival and OS along with ctDNA clearance are some of the secondary endpoints. The study has two stages: First 8 pts will receive the combination of neoadjuvant SG+Z to confirm tolerability. Once safety has been confirmed additional 8 pts will receive the triplet SG+Z+D. If no dose limiting toxicities are observed recruitment will continue to enroll a total of 70 patients. Patients will receive three Q3W neoadjuvant cycles of Z (360 mg day 1) + D (1200 mg day 1) plus SG (7.5 mg/m2 days 1 & 8) followed by cystectomy. After surgery, only those pts who do not achieve a pCR or that achieving a pCR still have positive ctDNA will receive 12 additional cycles of adjuvant treatment with only Z + D. The remaining will be followed with serial ctDNA and imaging. Clinical trial information: NCT06133517 .
Oral trehalose improves histological and behavior symptoms of mucopolysaccharidosis type II in iduronate 2-sulfatase deficient mice
Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).
154 Background: In 2004, docetaxel (DOC), a semi-synthetic taxane, received regulatory approval for mCRPC based on improved overall survival (OS). Cabazitaxel (CAB), a closely related analog of DOC, was approved in 2010 for mCRPC patients previously exposed to DOC. For patients previously treated with DOC, the relative benefits of docetaxel rechallenge (rDOC) versus a taxane switch to CAB are unknown. We aimed to evaluate the relative impact of rDOC versus CAB for patients who had previously received DOC for mCRPC. Methods: This retrospective cohort study compared outcomes of mCRPC patients in the nationwide VA healthcare system who received initial DOC, discontinued DOC for a reason other than disease progression, and later received rDOC or CAB after mCRPC diagnosis. Patients were eligible for inclusion if they received at least 3 cycles of DOC and at least 90 days later received a second course of DOC or CAB. The index date was the date of the start of the second course of taxane treatment. Time-to-event outcomes were evaluated from index date. Inverse probability of treatment weighting (IPTW) was used to control for potential confounders. Results: Between 1/2010 and 12/2023, a total of 669 patients (407 CAB, 262 rDOC) with median age 72, 29% Black, 27% CD, 39% CKD, 38% DM2, were included in final analysis. For the first instance of docetaxel, patients received a median of 6 (IQR: 4-10) cycles with a PSA50 = 20%, PSA90 = 3% and a median of 1 (IQR: 0-1) additional systemic treatment prior to subsequent taxane. At the time of the initiation of the second taxane, 73% of patients had bone and 18% visceral metastases and median initial PSA of 75 ng/mL. Compared to CAB, rDOC had higher PSA90 (11% vs 3%, p<0.001), longer OS (12.5 vs 9.6 months, p<0.001) and numerically longer time to next systemic treatment (16.4 vs 12.4 months, p=0.2), shorter time on treatment (2.1 vs. 2.6 months, p=0.56), and similar PSA50 (8% vs 9%, p=0.31). The use of platinum (9% vs 6%, p=0.15), immunotherapy (2 vs 1%, p=0.79) and PARP inhibitors (6% vs 5%, p=0.67) after the second instance of a taxane was not statistically different between groups. Conclusions: In this study, rDOC was associated with better survival and deeper response than cabazitaxel. The findings of this large-scale study provide guidance for making well-informed decisions about sequential use of taxanes for mCRPC treatment.
Efficacy and safety of apalutamide in metastatic castration sensitive prostate cancer patients with a prior history of cardiovascular or metabolic risk factors: A post-hoc analysis of the TITAN study.
165 Background: Patients with CV issues, such as MI, symptomatic congestive heart failure, or thromboembolic events occurring ≤6 months of randomization were excluded from the TITAN trial. However, patients with events occurring > 6 months prior or non-excluded CV conditions like IHD without MI were enrolled. Considering the demographics of prostate cancer and given prolonged ADT use may worsen existing co-morbid conditions, we conducted a post-hoc analysis to assess the efficacy and safety of apalutamide +ADT (APA) vs placebo+ADT(PBO) in patients with ≥ 1 risk factor or a history of CV or metabolic risk factors. Methods: CV and metabolic risk factors were categorized using MeDRA terminology and included CV ischemia, CV failure, CV arrhythmia, diabetes, hyperlipidemia, HT and obesity. Use of associated concomitant medications (con meds) were identified at study entry. Data from the final analysis after 44 months of median follow up were analysed for the co-primary endpoints of rPFS and OS, along with PSA90 or PSA<0.2ng/ml and TEAEs in patients with or without CV risk factors, and with con meds for these conditions. Results: In TITAN, 72% (378/524) and 69% (364/527) patients in the APA and PBO arms had a history of CV or metabolic risk factors at baseline; 68% (358/524) and 66% (347/527) were receiving con meds for these conditions. Individual risk factors were evenly matched between arms. All efficacy endpoints rPFS, OS, PSA90 and PSA<0.2ng/ml were superior in the APA group vs PBO group irrespective of CV/metabolic Risk and with con meds . Incidence of TEAEs were similar between subjects with and without CV & metabolic risk and with concomitant medications at baseline (Table). Conclusions: A large majority of patients enrolled in TITAN reflected an elderly population with a considerable CV risk profile. APA resulted in a significant improvement in both rPFS and OS and a favourable safety profile regardless of prior CV and metabolic baseline risk or with con meds at baseline for these conditions. Clinical trial information: NCT02489318 . With CV/metabolic risk factors at baseline Without CV/metabolic risk factors at baseline With CV/metabolic risk and concomitant medications at baseline APA+ADT ADT+Placebo APA+ADT ADT+Placebo APA+ADT ADT+Placebo Subgroup prevalence n(%) 378 (72.0%) 364 (69.1%) 147 (28.0%) 163 (30.9%) 358 (68.2%) 347 (65.8%) rPFS [HR (95% CI) p-value] 0.49 (0.38, 0.63) <0.0001 0.48 (0.33, 0.7) 0.0001 0.47 (0.36, 0.62) <0.0001 OS [HR (95% CI) p-value] 0.63 (0.5, 0.8) 0.0001 0.71 (0.49, 1.02) 0.0604 0.61 (0.48, 0.78) <0.0001 PSA90 or PSA<0.2ng/ml 326 (86.2%) 157 (43.1%) 121 (82.3%) 71 (43.6%) 307 (85.8%) 146 (42.1%) TEAE (all grades) 368 (97.4%) 353 (97.0%) 142 (97.3%) 157 (96.3%) 350 (97.8%) 337 (97.1%) Gr 3/4 TEAE 183 (48.4%) 165 (45.3%) 76 (52.1%) 55 (33.7%) 177 (49.4%) 161 (46.4%)